Streetbeat News

Earnings

SBUX

Starbucks reported better-than-expected Q4 financial results and comparable sales growth, leading to a rise in its share price.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 10:26 am

HAE

Haemonetics (NYSE:HAE) reported Q2 2024 earnings of $0.99 per share, beating the analyst consensus estimate of $0.89 by 11.24%. This is a 19.28% increase from the same period last year. The company also reported quarterly sales of $318.18 million, beating the analyst consensus estimate of $313.12 million by 1.62%, a 6.96% increase from the same period last year.

Portfolio Pulse from totan@benzinga.com

November 02, 2023 | 10:26 am

PRMW

Primo Water Corp has provided its Q4 revenue guidance in the range of $558M-$598M, compared to the estimated $579.84M. The company also reaffirmed its FY23 revenue guidance of $2.320B-$2.360B, against the estimated $2.34B.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 10:23 am

XRAY

Dentsply Sirona has revised its FY23 adjusted EPS guidance to $1.80-$1.85, down from the previous guidance of $1.92-$2.02. This is also below the consensus estimate of $1.98.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 10:23 am

XRAY

Dentsply Sirona has revised its FY23 organic sales growth to approximately 1%, with sales of $3.90B-$3.94B, compared to prior guidance of around 3% and consensus of $4.01B. The company's adjusted EPS is expected to be in the range of $1.80 to $1.85.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 10:22 am

PRMW

Primo Water reported Q3 adjusted earnings of $0.33 per share, beating the analyst consensus estimate of $0.27 by 22.22%. However, the company's quarterly sales of $622.00 million missed the analyst consensus estimate of $625.80 million by 0.61%. This represents a 50% increase in earnings and a 6.40% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 10:21 am

AUPH

Aurinia Pharmaceuticals has revised its FY23 sales guidance for Lupkynis (Voclosporin) to a range of $155M-$160M, a slight increase from the previous range of $150M-$160M.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 10:19 am

EPAM

EPAM Systems has revised its Q4 revenue forecast to $1.130B-$1.140B, higher than the estimated $1.15B, and adjusted EPS to $2.47-$2.55, also higher than the estimated $2.37. The company also revised its FY23 revenue to $4.663B-$4.673B from $4.65B-$4.70B, and adjusted EPS to $10.31-$10.39 from $9.90-$10.10.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 10:18 am

CVE

Cenovus Energy (NYSE:CVE) reported Q3 earnings of $0.72 per share, beating the analyst consensus estimate of $0.71 by 1.41%. This is a 16.13% increase from the same period last year. The company also reported quarterly sales of $12.90 billion, beating the analyst consensus estimate of $11.27 billion by 14.46%, despite a 3.85% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 10:17 am

GOLF

Acushnet, the company behind the GOLF ticker, has projected its FY23 revenue to be between $2.350B and $2.400B, which is significantly lower than the estimated $3.26B.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 10:16 am